Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV.
Eiichi OgawaNorihiro FurusyoMasayuki MurataKazuhiro ToyodaTakeo HayashiKazuya UraPublished in: Liver international : official journal of the International Association for the Study of the Liver (2017)
The titre of anti-HBs was significantly decreased from the early stage of DAA treatment. Chronic hepatitis C patients with resolved HBV infection and negative or very low-titre anti-HBs at baseline are at risk for having detectable HBV DNA transiently during treatment.